Compare DexCom, Inc. (DXCM) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Roundhill Magnificent Seven ETF — how do they compare? DexCom, Inc. trades at $77.82 (market cap $28.06B), while Roundhill Magnificent Seven ETF trades at $68.94. The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | MAGS | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Sector/Thematic |
52-Week High | $89.53 | $70.94 |
52-Week Low | $54.84 | $55.39 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
MAGS (Roundhill Magnificent Seven ETF) trades at $68.76, up 1.96% with a bullish technical signal from moving averages but overbought RSI readings. The ETF holds seven mega-cap tech stocks equally weighted, benefiting from AI-driven momentum but facing high concentration risk. Recent news highlights AI spending shifts from chipmakers to hyperscalers, with MAGS mentioned as a key vehicle for Magnificent Seven exposure.
Outlook remains positive due to AI infrastructure growth, but valuations are compressed for hyperscalers like Amazon and Microsoft. Risks include reliance on tech sector performance and potential rotation to small-caps. Analyst sentiment is mixed, with some seeing upside as AI revenues outpace capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
